Treatment of congenital neurotransmitter deficiencies by intracerebral ventricular injection of an adeno-associated virus serotype 9 vector

Human Gene Therapy

Volumn 25, Issue 3, 2014, Pages 189-198

  Lee, Ni Chung ^a,b   Chien, Yin Hsiu ^a   Hu, Min Hsiu ^a   Liu, Wen Shin ^a   Chen, Pin Wen ^a   Wang, Wei Hua ^a   Tzen, Kai Yuan ^a,c   Byrne, Barry J ^d   Hwu, Wuh Liang ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; DOPAMINE; NEUROTRANSMITTER; PARVOVIRUS VECTOR; SEROTONIN;

AADC GENE; ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS SEROTYPE 9; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; CONGENITAL DISORDER; CONTROLLED STUDY; DOPAMINE DEFICIENCY; DRUG SAFETY; GENE; GENE EXPRESSION; GENE MUTATION; GROWTH RATE; HINDLIMB; MOUSE; NEWBORN; NONHUMAN; SEROTONIN DEFICIENCY; SEROTYPE; SURVIVAL; VIRAL GENE THERAPY;

ANIMALS; ANIMALS, NEWBORN; AROMATIC-L-AMINO-ACID DECARBOXYLASES; BEHAVIOR, ANIMAL; BLOOD PRESSURE; BODY WEIGHT; BRAIN; BRAIN DISEASES, METABOLIC, INBORN; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; GENETIC THERAPY; GENETIC VECTORS; HUMANS; INJECTIONS, INTRAVENTRICULAR; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; NEUROTRANSMITTER AGENTS; TISSUE DISTRIBUTION;

EID: 84896321030     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2013.170     Document Type: Article

References (37)

1. Abeling, N.G., Van Gennip, A.H., Barth, P.G., et al. (1998). Aromatic L-amino acid decarboxylase deficiency: a new case with a mild clinical presentation and unexpected laboratory findings. J. Inherit. Metab. Dis. 21, 240-242.
2. Brautigam, C., Wevers, R.A., Hyland, K., et al. (2000). The influence of L-dopa on methylation capacity in aromatic L-amino acid decarboxylase deficiency: biochemical findings in two patients. J. Inherit. Metab. Dis. 23, 321-324.
3. Brun, L., Ngu, L.H., Keng, W.T., et al. (2010). Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency. Neurology 75, 64-71.
4. Cearley, C.N., Vandenberghe, L.H., Parente, M.K., et al. (2008). Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain. Mol. Ther. 16, 1710-1718.
5. Chtarto, A., Bockstael, O., Tshibangu, T., et al. (2013). A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting. Br. J. Clin. Pharmacol. 76, 217-232.
6. Ciesielska, A., Hadaczek, P., Mittermeyer, G., et al. (2013). Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses. Mol. Ther. 21, 158-166.
7. Crawley, J.N., Belknap, J.K., Collins, A., et al. (1997). Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology (Berl) 132, 107-124.
8. Cressant, A., Desmaris, N., Verot, L., et al. (2004). Improved behavior and neuropathology in the mouse model of Sanfi-lippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum. J. Neurosci. 24, 10229-10239.
9. Fiumara, A., Brautigam, C., Hyland, K., et al. (2002). Aromatic L-amino acid decarboxylase deficiency with hyperdopaminuria. Clinical and laboratory findings in response to different therapies. Neuropediatrics 33, 203-208.
10. Foust, K.D., Nurre, E., Montgomery, C.L., et al. (2009). In-travascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 27, 59-65.
11. Gadalla, K.K., Bailey, M.E., Spike, R.C., et al. (2013). Improved survival and reduced phenotypic severity following AAV9/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice. Mol. Ther. 21, 18-30.
12. Hamosh, A., and Mckusick, V.A. (2011). DOPA DECARBOX-YLASE; DDC. OMIM Database, Johns Hopkins University, Baltimore, MD.
13. Homanics, G.E., Quinlan, J.J., and Firestone, L.L. (1999). Pharma-cologic and behavioral responses of inbred C57BL/6J and strain 129/SvJ mouse lines. Pharmacol. Biochem. Behav. 63, 21-26.
14. Hwu, W.L., Muramatsu, S., Tseng, S.H., et al. (2012). Gene therapy for aromatic L-amino acid decarboxylase deficiency. Sci. Transl. Med. 4, 134ra61.
15. Hyland, K., and Clayton, P.T. (1990). Aromatic amino acid decarboxylase deficiency in twins. J. Inherit. Metab. Dis. 13, 301-304.
16. Hyland, K., Surtees, R.A., Rodeck, C., and Clayton, P.T. (1992). Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a new inborn error of neu-rotransmitter amine synthesis. Neurology 42, 1980-1988.
17. Kim, J.Y., Ash, R.T., Ceballos-Diaz, C., et al. (2013). Viral trans-duction of the neonatal brain delivers controllable genetic mosaicism for visualising and manipulating neuronal circuits in vivo. Eur. J. Neurosci. 37, 1203-1220.
18. Korenke, G.C., Christen, H.J., Hyland, K., et al. (1997). Aromatic L-amino acid decarboxylase deficiency: an extrapyramidal movement disorder with oculogyric crises. Eur. J. Paediatr. Neurol. 1, 67-71.
19. Lee, N.C., Shieh, Y.D., Chien, Y.H., et al. (2013). Regulation of the dopaminergic system in a murine model of aromatic l-amino acid decarboxylase deficiency. Neurobiol. Dis. 52C, 177-190.
20. Lin, C.J., Tai, Y., Huang, M.T., et al. (2010). Cellular localization of the organic cation transporters, OCT1 and OCT2, in brain microvessel endothelial cells and its implication for MPTP transport across the blood-brain barrier and MPTP-induced dopaminergic toxicity in rodents. J. Neurochem. 114, 717-727.
21. Maller, A., Hyland, K., Milstien, S., et al. (1997). Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a second family. J. Child Neurol. 12, 349-354.
22. Manegold, C., Hoffmann, G.F., Degen, I., et al. (2009). Aromatic L-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-up. J. Inherit. Metab. Dis. 32, 371-380.
23. Miyake, N., Miyake, K., Yamamoto, M., et al. (2011). Global gene transfer into the CNS across the BBB after neonatal systemic delivery of single-stranded AAV vectors. Brain Res. 1389, 19-26.
24. Montioli, R., Oppici, E., Cellini, B., et al. (2013). S250F variant associated with aromatic amino acid decarboxylase deficiency: molecular defects and intracellular rescue by pyridoxine. Hum. Mol. Genet. 22, 1615-1624.
25. Patel, B.A., Arundell, M., Parker, K.H., et al. (2005). Simple and rapid determination of serotonin and catecholamines in biological tissue using high-performance liquid chromatography with electrochemical detection. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 818, 269-276.
26. Pons, R., Ford, B., Chiriboga, C.A., et al. (2004). Aromatic L-amino acid decarboxylase deficiency: clinical features, treatment, and prognosis. Neurology 62, 1058-1065.
27. Rahim, A.A., Wong, A.M., Hoefer, K., et al. (2011). Intravenous administration of AAV2/9 to the fetal and neonatal mouse leads to differential targeting of CNS cell types and extensive transduction of the nervous system. FASEB J. 25, 3505-3518.
28. Rozas, G., Guerra, M.J., and Labandeira-Garcia, J.L. (1997). An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res. Brain Res. Protoc. 2, 75-84.
29. Swoboda, K.J., Hyland, K., Goldstein, D.S., et al. (1999). Clinical and therapeutic observations in aromatic L-amino acid dec-arboxylase deficiency. Neurology 53, 1205-1211.
30. Swoboda, K.J., Saul, J.P., Mckenna, C.E., et al. (2003). Aromatic L-amino acid decarboxylase deficiency: overview of clinical features and outcomes. Ann. Neurol. 54 Suppl. 6, S49-S55.
31. Tay, S.K., Poh, K.S., Hyland, K., et al. (2007). Unusually mild phenotype of AADC deficiency in 2 siblings. Mol. Genet. Metab. 91, 374-378.
32. Verbeek, M.M., Geurtz, P.B., Willemsen, M.A., and Wevers, R.A. (2007). Aromatic L-amino acid decarboxylase enzyme activity in deficient patients and heterozygotes. Mol. Genet. Metab. 90, 363-369.
33. Vuckovic, M.G., Li, Q., Fisher, B., et al. (2010). Exercise elevates dopamine D2 receptor in a mouse model of Parkinson's disease: in vivo imaging with [(1)F]fallypride. Mov. Disord. 25, 2777-2784.
34. Wassenberg, T., Willemsen, M.A., Geurtz, P.B., et al. (2010). Urinary dopamine in aromatic L-amino acid decarboxylase deficiency: the unsolved paradox. Mol. Genet. Metab. 101, 349-356.
35. Wu, W.L., Lin, Y.W., Min, M.Y., and Chen, C.C. (2010). Mice lacking Asic3 show reduced anxiety-like behavior on the elevated plus maze and reduced aggression. Genes Brain Behav. 9, 603-614.
36. Zeiss, C.J. (2005). Neuroanatomical phenotyping in the mouse: the dopaminergic system. Vet. Pathol. 42, 753-773.
37. Zolotukhin, S., Potter, M., Zolotukhin, I., et al. (2002). Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28, 158-167.